Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...

Urolithiasis is a highly prevalent and multifactorial disease, representing the most common urological condition globally.

The researchers then investigated how the metabolisms of treated mice changed. They found that the effect was caused by ...

Researchers say semaglutide may help reverse MASH, a progressive liver condition affecting millions of Americans.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...